… management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management
of atrial fibrillation. … Dabigatran etexilate: the first oral anticoagulant available in the United …

… Dabigatran, rivaroxaban, and apixaban are all being investigated for a broad range of …
including management of atrial fibrillation, acute coronary syndromes, and the treatment and …

… in moderate- to high-risk 560 AF patients in Greece [70]. Although effective, the use of
vitamin K … •• This meta-analysis showed in patients with atrial fibrillation (AF) that adjusted-dose …

… in order to assess the anticoagulant effects of dabigatran etexilate in patients with NV-AF. …
, Athens, Greece. The 20 patients in group A received the standard dose of Pradaxa (110 mg …

… As far as we know, other economic studies have focused on the cost effectiveness of …
from $US7508 per QALY in Greece to $US36,810 per QALY in the UK [15, 17]. A cost-effectiveness …

… .1,2 The data show that dabigatran etexilate was the most widely prescribed NOAC for stroke
… patients with atrial fibrillation receive the most effective anticoagulant treatment to reduce …

… Dabigatran etexilate** Initial therapy with parenteral anticoagulation for 5–10 days … for
the prevention of embolic complications in patients with atrial fibrillation.Accumulating “real-world” …

… Cost-effectiveness of dabigatran etexilate for stroke prevention in non-valvular atrial
fibrillation. … Economic factors associated with antithrombotic treatments for stroke prevention in …

… and overall stroke between IS patients with atrial fibrillation randomized to apixaban in
AVERROES and ESUS patients randomized to dabigatran in RE-SPECT ESUS (Table 4). …